Alecensa (alectinib) — United Healthcare
B-Cell Lymphomas
Initial criteria
- Diagnosis of large B-Cell lymphoma
- Disease is one of the following: relapsed OR refractory
- Anaplastic lymphoma kinase (ALK)-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Alecensa therapy
Approval duration
12 months